Skip to main content
Clinical Trials/NCT03058016
NCT03058016
Unknown
Not Applicable

Personalized Nutrition Prediction for Metabolic Syndrome Patients, an Open Single-center Study

Galilee CBR0 sites500 target enrollmentApril 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metabolic Syndrome
Sponsor
Galilee CBR
Enrollment
500
Primary Endpoint
To determine number of participants with reduced BMI
Last Updated
9 years ago

Overview

Brief Summary

This clinical study is designed to evaluate the providing of a computational prediction engine for optimization of personalized nutrition

Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month.

Detailed Description

Pre-diabetic and pre-metabolic syndrome patients will be recruited to the study for a period of one year. After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built. Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month.

Registry
clinicaltrials.gov
Start Date
April 1, 2017
End Date
April 1, 2022
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Galilee CBR
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adults age 18-65
  • HBA1C between 5.5 and 7%.
  • Altered lipid metabolism
  • Signed Informed Consent

Exclusion Criteria

  • Usage of antibiotics within three months prior to participation
  • Chronically active inflammatory or neoplastic disease in the three years prior to enrollment
  • Chronic gastrointestinal disorder, including Inflammatory Bowel Disease and Celiac Disease
  • Skin disease, including contact dermatitis, precluding proper attachment of the continuous glucose monitor
  • Active psychiatric disorder
  • Myocardial infarction or cerebrovascular accident in the 6 months prior to participation
  • Chronic immunosuppressive medication usage
  • Clinical depression

Outcomes

Primary Outcomes

To determine number of participants with reduced BMI

Time Frame: One year

Change at 12 months

To determine number of participants with reduced hA1C

Time Frame: One year

Change at 12 months

To determine number of participants with reduced cholesterol

Time Frame: One year

Change at 12 months

Secondary Outcomes

  • Type of intestinal microorganisms(One year)
  • Number of intestinal microorganisms(One year)

Similar Trials